Author Bio
A Fool since 2019, Prosper s writing focuses primarily on the healthcare sector. Passionate about teaching and learning, he enjoys helping others make better decisions about their finances and enjoys it just as much when they return the favor. In his free time, you ll find him curling up with a good book or doing math.
What happened?
Shares of
9 Meters Biopharma (NASDAQ:NMTR), a clinical-stage biotech company, are trading higher on Wednesday after the company filed documents with the U.S. Securities and Exchange Commission (SEC) indicating that several of its executives have recently purchased shares of the company. As of 1:24 p.m. EDT, 9 Meters Biopharma s stock was up by 10.8% after jumping by as much as 18% earlier in the day.
9 Meters Biopharma, Inc. highlighted at upcoming Truist Securities CEO Strategic Vision Conference Call Series
RALEIGH, NC / ACCESSWIRE / February 3, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced its Executive Management team will participate in the CEO Strategic Vision Conference Call Series hosted by hosted by Srikripa Devarakonda, PhD and Robyn Karnauskas, PhD of Truist Securities on Wednesday, February 10, 2021. Please see additional details below:
CEO Strategic Vision Conference Call Series
Date: Wednesday, February 10, 2021
Time: 11:00 am Eastern Time
Speakers: President & CEO, John Temperato
CFO, Edward Sitar
SVP Corporate Development & Operations, Sireesh Appajosyula
Conference Details: To register please contact your Truist Securities sales representative